The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Sandoz Inc., a global pharmaceutical and biosimilar provider, to supply a variety of prescription medications through the VA and Department of Defense (DoD) pharmaceutical prime vendor programs. The contract has a base period of one year and four one-year option periods, with a total ceiling value of $9,803,319.55.
The contract aims to provide an uninterrupted source of supply for Bumetanide tablets in various dosages to serve the medication needs of veterans, active duty military personnel, federal inmates, and Native American populations across the VA, DoD, Bureau of Prisons, and Indian Health Services healthcare networks. The contract was awarded on an unrestricted basis with no set-asides, allowing Sandoz Inc. to distribute products from its commercial catalogs through the established prime vendor programs. The contract identifies estimated annual requirements for the Bumetanide tablet products to be ordered under the IDC.
Generated 12/27/24, 9:06 AM